DE69533941D1 - Verfahren zur herstellung eines arzneimittels zur behandlung des sekundärimmunmangels - Google Patents

Verfahren zur herstellung eines arzneimittels zur behandlung des sekundärimmunmangels

Info

Publication number
DE69533941D1
DE69533941D1 DE69533941T DE69533941T DE69533941D1 DE 69533941 D1 DE69533941 D1 DE 69533941D1 DE 69533941 T DE69533941 T DE 69533941T DE 69533941 T DE69533941 T DE 69533941T DE 69533941 D1 DE69533941 D1 DE 69533941D1
Authority
DE
Germany
Prior art keywords
medicament
treating
production
secondary immune
lymphocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69533941T
Other languages
English (en)
Other versions
DE69533941T2 (de
Inventor
John W Hadden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Florida
Original Assignee
University of South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of South Florida filed Critical University of South Florida
Publication of DE69533941D1 publication Critical patent/DE69533941D1/de
Application granted granted Critical
Publication of DE69533941T2 publication Critical patent/DE69533941T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/59—Lectins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
DE69533941T 1994-11-17 1995-11-16 Verfahren zur herstellung eines arzneimittels zur behandlung des sekundärimmunmangels Expired - Lifetime DE69533941T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34164594A 1994-11-17 1994-11-17
US341645 1994-11-17
PCT/US1995/015492 WO1996015808A1 (en) 1994-11-17 1995-11-16 Method for making a medicament for treating secondary immunodeficiency

Publications (2)

Publication Number Publication Date
DE69533941D1 true DE69533941D1 (de) 2005-02-24
DE69533941T2 DE69533941T2 (de) 2005-12-29

Family

ID=23338440

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69533941T Expired - Lifetime DE69533941T2 (de) 1994-11-17 1995-11-16 Verfahren zur herstellung eines arzneimittels zur behandlung des sekundärimmunmangels

Country Status (11)

Country Link
US (1) US5698194A (de)
EP (1) EP0789588B1 (de)
JP (4) JP4440342B2 (de)
AT (1) ATE287270T1 (de)
AU (1) AU694304B2 (de)
CA (1) CA2205430C (de)
DE (1) DE69533941T2 (de)
DK (1) DK0789588T3 (de)
ES (1) ES2236719T3 (de)
PT (1) PT789588E (de)
WO (1) WO1996015808A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3497607B2 (ja) * 1995-05-26 2004-02-16 オリンパス株式会社 接眼光学系及びそれを用いた画像表示装置
JP2002516562A (ja) * 1996-03-04 2002-06-04 ターゲティッド ジェネティックス コーポレイション Ｔリンパ球のインビトロ増殖のための改変された迅速な拡大方法（「改変ｒｅｍ」）
US6344192B1 (en) * 1997-02-21 2002-02-05 Vlaams Interuniversitair Instituut Voor Biotechnologie Use of interleukin-15
AU748467B2 (en) * 1997-10-17 2002-06-06 University Of South Florida Method to diagnose and monitor cellular immune deficiencies
DE60009533T2 (de) * 1999-10-13 2005-01-27 Incyte Corp., Palo Alto Multiple analyse von zytokinen
US20020150541A1 (en) * 2000-09-12 2002-10-17 Gene Trol Biotherapeutics, Inc. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
US20030129162A1 (en) * 2000-09-12 2003-07-10 Lau Allan S. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
EP1318834A2 (de) * 2000-09-12 2003-06-18 Genetrol Biotherapeutics, Inc. Zusammensetzung, die eine mischung von menschlichen zytokinen enthält, sowie verfahren für ihre herstellung
US20060194242A1 (en) * 2000-10-27 2006-08-31 Hadden John W Immunotherapy for immune suppressed patients
US20070031372A1 (en) * 2004-08-05 2007-02-08 Hadden John W Vaccine immunotherapy for immune suppressed patients
US7182942B2 (en) * 2000-10-27 2007-02-27 Irx Therapeutics, Inc. Vaccine immunotherapy for immune suppressed patients
US20070154399A1 (en) 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
MXPA03003638A (es) 2000-10-27 2004-01-26 Immuno Rx Inc Inmunoterapia con vacuna para pacientes inmunosuprimidos.
WO2003035004A2 (en) * 2001-10-26 2003-05-01 Immuno-Rx, Inc. Immunotherapy for reversing immune suppression
US6896879B2 (en) * 2003-07-03 2005-05-24 Cel-Sci Corporation Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
US20050002899A1 (en) * 2003-07-03 2005-01-06 Eyal Talor Method of pre-sensitizing cancer prior to treament with radiation and/or chemotherapy and a novel cytokine mixture
WO2005046746A2 (en) * 2003-11-10 2005-05-26 Angiotech International Ag Medical implants and fibrosis-inducing agents
JP2008501697A (ja) * 2004-06-04 2008-01-24 セル‐サイ コーポレイション Ｃｄ４／ｃｄ８比及び腫瘍への単核細胞浸潤を変化させる方法
CA2574970A1 (en) * 2004-07-30 2006-02-09 Cel-Sci Corporation A method for managing cholesterol with a serum-free and mitogen-free cytokine mixture
US20060257357A1 (en) * 2005-05-10 2006-11-16 Cel-Sci Corporation Method for modulating HLA class II tumor cell surface expression with a cytokine mixture
US7993660B2 (en) 2007-11-28 2011-08-09 Irx Therapeutics, Inc. Method of increasing immunological effect
CA2758834C (en) * 2008-04-14 2017-11-07 Irx Therapeutics, Inc. Primary cell derived biologic modified manufacturing process
DK2429585T3 (en) 2009-05-15 2018-07-30 Irx Therapeutics Inc VACCINE IMMUNOTHERAPY
AU2010328197B2 (en) 2009-12-08 2015-07-16 Irx Therapeutics, Inc. Method of reversing immune suppression of Langerhans cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4390623A (en) * 1980-10-02 1983-06-28 Hooper Trading Company Serum-free and mitogen-free T-cell growth factor and process for making same
US4464355A (en) * 1981-03-26 1984-08-07 Hooper Trading Co. Serum-free and mitogen-free T-cell growth factor and process for making same
US4448879A (en) * 1981-03-26 1984-05-15 Hooper Trading Company High yield process for in vitro production of serum-free and mitogen-free interleukin-2
SE8801426D0 (sv) * 1988-04-15 1988-04-15 Ulf Rothman Forfarande och medel for blodbehandling

Also Published As

Publication number Publication date
ES2236719T3 (es) 2005-07-16
MX9703626A (es) 1998-12-31
US5698194A (en) 1997-12-16
AU4411196A (en) 1996-06-17
EP0789588A1 (de) 1997-08-20
DE69533941T2 (de) 2005-12-29
JP4440342B2 (ja) 2010-03-24
DK0789588T3 (da) 2005-05-30
JPH10510147A (ja) 1998-10-06
CA2205430A1 (en) 1996-05-30
WO1996015808A1 (en) 1996-05-30
JP2005245455A (ja) 2005-09-15
ATE287270T1 (de) 2005-02-15
EP0789588B1 (de) 2005-01-19
PT789588E (pt) 2005-05-31
CA2205430C (en) 2001-09-04
JP2007236395A (ja) 2007-09-20
AU694304B2 (en) 1998-07-16
EP0789588A4 (de) 2001-11-28
JP2009209164A (ja) 2009-09-17

Similar Documents

Publication Publication Date Title
DE69533941D1 (de) Verfahren zur herstellung eines arzneimittels zur behandlung des sekundärimmunmangels
Hunter et al. Histochemical demonstration of enzymes separated by zone electrophoresis in starch gels
CA1083987A (en) Process for serially culturing keratinocytes
DE69333433D1 (de) Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
CA2087525A1 (en) Adoptive immunotherapy with interleukin-7
AU7769887A (en) Apparatus and methods of culturing motile microorganisms
IL96779A0 (en) Process for the production and extraction of antioxidants from a micro-organism culture and photobioreactor for performing this process
CA1267623C (en) CELL CULTURE FILTER APPARATUS AND METHOD OF USE
KR960009482B1 (en) Method for preserving transplantable sheets of epithelium cultured in vitro
AU4277689A (en) Process for producing cultured epidermal sheet, product and method of use
FI894001A0 (fi) Vaextgummimaterial och dess anvaendning i livsmedelsprodukter.
EP0340783A3 (en) Apparatus for culturing animal cells, method of culturing thereof and diagnostics of the culture
EP0205387A3 (en) Human monocytes cultured in suspension in serum-free medium
Mayyasi et al. Cultivation of L strain (Earle) mouse cells in bacteriological media combined with horse serum
Scheicher et al. Recombinant GM-CSF induces in vitro differentiation of dendritic cells from mouse bone marrow
EP0201800A3 (en) A cholesterol-rich fraction, process therefor and use thereof in cell culture
WO1987007640A1 (en) Process for preparing neuraminidase
GR3031236T3 (en) Process for the preparation of pilocarpine.
EP0299067A4 (de) Zuchtmedium für pflanzen.
PT83368A (en) Process for propagating microorganisms in vivo by using cell lines which lack human class ii histocompatibility antigens
PL239589A1 (en) Agent for use reproduction process of cultivable plants by means of tissue culture in vitro and method of increasing reproduction rate of cultivable plants by means of tissue culture in vitro
Evans Thymic reticuloepithelial cell products: role in hematopoietic cell differentiation.
DE69022121D1 (de) Verfahren zur Herstellung eines Metastaseninhibitorenfaktors.
JPS5794290A (en) Method for producing interferon
Laforest et al. Stimulation of granulopoiesis after removal of cells released by newborn mouse spleen in organ culture

Legal Events

Date Code Title Description
8364 No opposition during term of opposition